King-Jones Heidy sold SYRE
September 1, 2026 · Form 4 insider transaction
King-Jones Heidy sold 400 shares of Spyre Therapeutics, Inc. at $89.38 per share, a transaction worth $35.8K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.; Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan.